ALNY Q1 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$594M+20.2% YoY

Gross Profit

$523M88.0% margin

Operating Income

$18M3.0% margin

Net Income

-$57M-9.7% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

-$118M

Free Cash Flow

-$127M

Stock-Based Comp.

$57M

Balance Sheet

Total Assets

$4.2B

Total Liabilities

$4.1B

Stockholders' Equity

$115M

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$594M	$494M	+20.2%
Gross Profit	$523M	$428M	+22.1%
Operating Income	$18M	-$43M	+141.6%
Net Income	-$57M	-$66M	+12.8%

Revenue Segments

Product

$469M80%

GIVLAARI

$67M11%

ONPATTRO

$49M8%

Geographic Segments

UNITED STATES

$198M64%

Europe

$80M26%

Non-US Or Europe

$32M10%